An exclusionary approach to recover Iron deficiency by POLYROL: an over view of Iron Polymaltose complex

The current review is based on Iron (III)-hydroxide polymaltose complex that shows that iron is meaningfully bioavailable after oral administration, especially in iron-deficient patients. Iron (III) hydroxide polymaltose complex (IPC) is an iron preparation with non-ionic iron and polymaltose in a stable composite. Since past decades so many research organizations has conducted clinical trials in men, women, children and infants and have shown that IPC is effective in treating iron deficiency anaemia (IDA). Researchers concluded that because of its kinetic properties, IPC is best given with meals, and probably in an iron dose slightly higher than that of the classical iron salts. Furthermore in terms of acceptance and patient compatibility, IPC presents a clear benefit as compare to ferrous salts. So many research and published works have shown a lower rate of treatment interruption with IPC than with ferrous salts. This is usually associated with a lower incidence of adverse events related to the upper gastro